Bioactivity | Beclometasone (Beclomethasone) is a prototype glucocorticoid receptor agonist. | ||||||||||||
Target | Glucocorticoid Receptor | ||||||||||||
Invitro | An inhibition of the normal physiological neutrophil migration and of neutrophil chemotaxis directed by wounding-induced inflammation is detected at 4 h after administration of 25 μM Beclomethasone. Tumour cell invasion and micrometastasis is also reduced in embryos incubated in 25 μM Beclomethasone 4 h before implantation. In addition, the lysyl oxidase inhibitor β-aminoproprionitrile (βAPN) largely reduces fibrillar collagen and enhances the CHT-TF transmigration of neutrophils, leading to a significant increase of tumour cell invasion and subsequent formation of micrometastases. Notably, βAPN inhibits neutrophil chemotaxis induced by inflammation, indicating that the increase of tumour cell invasion in βAPN-treated embryos is correlated with enhanced non-pathological neutrophil migration, but not with inflammation[1]. | ||||||||||||
Name | Beclometasone | ||||||||||||
CAS | 4419-39-0 | ||||||||||||
Formula | C22H29ClO5 | ||||||||||||
Molar Mass | 408.92 | ||||||||||||
Appearance | Solid | ||||||||||||
Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
Storage |
|
||||||||||||
Reference | [1]. He S, et al. Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model. J Pathol. 2012 Aug;227(4):431-45. |